AVTE - Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference | Benzinga
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced an upcoming poster presentation at the 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, in San Diego, CA. The presentation will provide baseline characteristics from patients enrolled in the dose-ranging Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial evaluating the safety and efficacy of AV-101 in adults with pulmonary arterial hypertension.
"We look forward to presenting baseline characteristics of the Phase 2b portion of the IMPAHCT trial in our poster presentation at the upcoming ATS conference in May," said Tim Noyes, Chief Executive Officer at Aerovate Therapeutics. "These data will provide insight into the IMPAHCT patient population as we continue Phase 3 trial recruitment globally and expect to present top line Phase 2b data in June."
Details for the poster presentation are as follows:
Poster Session: C62. Top Gun: Novel Therapeutics And Outcomes In Pulmonary Arterial Hypertension
Date: Tuesday, May 21, 2024
Presentation Time: 11:30 a.m. – 1:15 p.m. PT
Location: Session Room TDP29
Abstract: Baseline characteristics from the IMPAHCT trial of AV-101, inhaled imatinib, in subjects with pulmonary arterial hypertension
Presenter: Hunter Gillies, MBChB
The poster abstract is available now on the 2024 ATS website. The abstract includes data from 147 patients, and the poster presentation on May 21st will include baseline characteristics for all 202 Phase 2b patients.
About AV-101
AV-101 is an investigational, proprietary dry powder inhaled formulation of the antiproliferative drug imatinib. Developed specifically for pulmonary arterial hypertension (PAH), AV-101 targets cellular hyperproliferation and resistance to apoptosis, driven by improper signaling in cells of the distal pulmonary arteries. By targeting the proliferation and accumulation of cells in the arteries of the lungs, we believe AV-101 has the potential to provide meaningful improvements for patients beyond the capabilities of currently approved therapies. AV-101 ...